About Polyphor
Polyphor is a publicly listed company based in Allschwil (Switzerland) founded in 1996 by Daniel Obrecht. Macrocycle drugs are developed for infections, cancer, and cystic fibrosis. Polyphor has raised $39.68 million across 4 funding rounds from investors including Cystic Fibrosis Foundation, CARB-X and Novo Holdings. Polyphor offers products and services including Inhaled Murepavadin and Balixafortide. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Spexis AG.
Company details
Polyphor was founded in 1996 in Allschwil, Switzerland, and operates in the biotechnology sector. Macrocycle drugs are developed by the company for treating infections, breast cancer, cystic fibrosis, and related conditions. Proprietary technologies such as PEMfinder and MacroFinder are utilized in its pipeline, which includes Murepavadin for Pseudomonas infections in Phase 2, POL6326 for metastatic breast cancer and myelodysplastic syndromes, and POL6014 for cystic fibrosis and alpha-1 antitrypsin deficiency.
- Headquarters Allschwil, Switzerland
- Founders Daniel Obrecht
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website polyphor.com
- Legal Name Spexis Ag
- Annual Revenue$6.69 M (USD)2379as on Dec 31, 2018
- Total Equity Funding$39.68M (USD)
in 4 rounds
- InvestorsCystic Fibrosis Foundation
& 2 more
Products & Services of Polyphor
Polyphor offers a comprehensive portfolio of products and services, including Inhaled Murepavadin and Balixafortide.
Inhaled treatment for Pseudomonas aeruginosa infections in cystic fibrosis
CXCR4 inhibitor for potential cancer and related indications
Funding Insights of Polyphor
Polyphor has successfully raised a total of $39.68M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.68M
- Total Rounds 4
- First Round $39.68M
(Apr 2017)
- Investors Count 3
All 4 funding rounds of Polyphor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | Grant | – | – | ||
| Oct 2020 | Grant | – | – | ||
| Sep 2018 | $6.99M | Post-IPO | – | – | |
| Apr 2017 | $39.68M | Private Equity Round | – | – | – |
3 investors in total: 3 institutional.
Investors in Polyphor
Polyphor has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Cystic Fibrosis Foundation, CARB-X and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Research funding and support for cystic fibrosis patients are provided. | 1955 | cff.org | Bethesda, United States | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States |
Investor details for Polyphor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Polyphor
9 people are tracked at Polyphor (5 in leadership, 4 in board & advisors).
| Name | Role | Group |
|---|---|---|
Daniel Obrecht | Co-Founder | Leadership |
Jeffrey D. Wager | CEO | Leadership |
Hernan Levett | Chief Financial Officer | Leadership |
Juergen Froehlich | Chief Medical Officer | Leadership |
Muriel Fleming | Chief Administration / Operations And HR Officer | Leadership |
Kuno Sommer | Board Member | Board & advisors |
Dan Hartman | Board Member | Board & advisors |
Robert Clarke | Board Member | Board & advisors |
Dennis A. Ausiello | Vice Chairman | Board & advisors |
Complete people profiles for Polyphor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Polyphor
4 dated milestones of Polyphor across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Polyphor is founded.
- Funding First funding round of $39.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant,.
Web traffic of Polyphor
Websites that share an audience with Polyphor (polyphor.com).
Websites whose visitors overlap most with Polyphor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| numerate.com | 100% | View details | |||
| jubilantbiosys.com | 100% | 12.2K | #2,731,637 | View details | |
| argentadiscovery.com | 99% | View details | |||
| pevion.com | 39% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Polyphor
Complete news archive for Polyphor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Polyphor
Polyphor was founded in 1996 and raised its 1st funding round 21 years after it was founded.
Polyphor is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Polyphor is a funded company, having raised a total of $39.68M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $39.68M, raised on Apr 2017.
Annual revenue of Polyphor is $6.69M as on Dec 31, 2018.
Polyphor was founded in 1996 in Allschwil, Switzerland, and operates in the biotechnology sector. Macrocycle drugs are developed by the company for treating infections, breast cancer, cystic fibrosis, and related conditions. Proprietary technologies such as PEMfinder and MacroFinder are utilized in its pipeline, which includes Murepavadin for Pseudomonas infections in Phase 2, POL6326 for metastatic breast cancer and myelodysplastic syndromes, and POL6014 for cystic fibrosis and alpha-1 antitrypsin deficiency.
Polyphor offers Inhaled Murepavadin and Balixafortide.
Polyphor has 3 investors. Key investors include Cystic Fibrosis Foundation, CARB-X, and Novo Holdings.
Polyphor operates through Spexis Ag.